APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

mRNA COVID-19 Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global mRNA COVID-19 Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174014600422 December 2025192 pages

Choose your research edition.

Industry ResearchmRNA COVID-19 Vaccine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA COVID-19 Vaccine Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal mRNA COVID-19 Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA COVID-19 Vaccine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA COVID-19 Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global mRNA COVID-19 Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for mRNA COVID-19 Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for mRNA COVID-19 Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for mRNA COVID-19 Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the mRNA COVID-19 Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the mRNA COVID-19 Vaccine market include CSPC Pharmaceutical, CanSino Biologicals, Pfizer, Fosun-Pharmaceutical and Moderna, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global mRNA COVID-19 Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of mRNA COVID-19 Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents mRNA COVID-19 Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the mRNA COVID-19 Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

mRNA COVID-19 Vaccine Segment by Company

CSPC Pharmaceutical

CanSino Biologicals

Pfizer

Fosun-Pharmaceutical

Moderna

mRNA COVID-19 Vaccine Segment by Type

Non-replicating mRNA Vaccine

Self-amplifying mRNA Vaccine

mRNA COVID-19 Vaccine Segment by Application

Children

Adults

mRNA COVID-19 Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global mRNA COVID-19 Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions mRNA COVID-19 Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify mRNA COVID-19 Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze mRNA COVID-19 Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA COVID-19 Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA COVID-19 Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA COVID-19 Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the mRNA COVID-19 Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA COVID-19 Vaccine industry.

Chapter 3: Detailed analysis of mRNA COVID-19 Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of mRNA COVID-19 Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of mRNA COVID-19 Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. mRNA COVID-19 Vaccine Industry Trends Table 2. mRNA COVID-19 Vaccine Industry Drivers Table 3. mRNA COVID-19 Vaccine Industry Opportunities and Challenges Table 4. mRNA COVID-19 Vaccine Industry Restraints Table 5. Global mRNA COVID-19 Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global mRNA COVID-19 Vaccine Revenue Share by Company (2021-2026) Table 7. Global mRNA COVID-19 Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global mRNA COVID-19 Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global mRNA COVID-19 Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global mRNA COVID-19 Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global mRNA COVID-19 Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global mRNA COVID-19 Vaccine Company, Product Type & Application Table 13. Global mRNA COVID-19 Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global mRNA COVID-19 Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Non-replicating mRNA Vaccine Table 18. Significant Companies of Self-amplifying mRNA Vaccine Table 19. Global mRNA COVID-19 Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global mRNA COVID-19 Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global mRNA COVID-19 Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global mRNA COVID-19 Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global mRNA COVID-19 Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global mRNA COVID-19 Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global mRNA COVID-19 Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global mRNA COVID-19 Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global mRNA COVID-19 Vaccine Sales Value Share by Type (2021-2026) Table 28. Global mRNA COVID-19 Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Children Table 30. Significant Companies of Adults Table 31. Global mRNA COVID-19 Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global mRNA COVID-19 Vaccine Sales Volume by Application (2021-2026) & (k units) Table 33. Global mRNA COVID-19 Vaccine Sales Volume by Application (2027-2032) & (k units) Table 34. Global mRNA COVID-19 Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global mRNA COVID-19 Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global mRNA COVID-19 Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global mRNA COVID-19 Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global mRNA COVID-19 Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global mRNA COVID-19 Vaccine Sales Value Share by Application (2021-2026) Table 40. Global mRNA COVID-19 Vaccine Sales Value Share by Application (2027-2032) Table 41. Global mRNA COVID-19 Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global mRNA COVID-19 Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global mRNA COVID-19 Vaccine Sales Market Share by Region (2021-2026) Table 44. Global mRNA COVID-19 Vaccine Sales by Region (2027-2032) & (k units) Table 45. Global mRNA COVID-19 Vaccine Sales Market Share by Region (2027-2032) Table 46. Global mRNA COVID-19 Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global mRNA COVID-19 Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global mRNA COVID-19 Vaccine Sales Value Share by Region (2021-2026) Table 49. Global mRNA COVID-19 Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global mRNA COVID-19 Vaccine Sales Value Share by Region (2027-2032) Table 51. Global mRNA COVID-19 Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global mRNA COVID-19 Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global mRNA COVID-19 Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global mRNA COVID-19 Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global mRNA COVID-19 Vaccine Sales by Country (2021-2026) & (k units) Table 56. Global mRNA COVID-19 Vaccine Sales Market Share by Country (2021-2026) Table 57. Global mRNA COVID-19 Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global mRNA COVID-19 Vaccine Sales Market Share by Country (2027-2032) Table 59. Global mRNA COVID-19 Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global mRNA COVID-19 Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global mRNA COVID-19 Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global mRNA COVID-19 Vaccine Sales Value Market Share by Country (2027-2032) Table 63. CSPC Pharmaceutical Company Information Table 64. CSPC Pharmaceutical Business Overview Table 65. CSPC Pharmaceutical mRNA COVID-19 Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. CSPC Pharmaceutical mRNA COVID-19 Vaccine Product Portfolio Table 67. CSPC Pharmaceutical Recent Development Table 68. CanSino Biologicals Company Information Table 69. CanSino Biologicals Business Overview Table 70. CanSino Biologicals mRNA COVID-19 Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. CanSino Biologicals mRNA COVID-19 Vaccine Product Portfolio Table 72. CanSino Biologicals Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer mRNA COVID-19 Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Pfizer mRNA COVID-19 Vaccine Product Portfolio Table 77. Pfizer Recent Development Table 78. Fosun-Pharmaceutical Company Information Table 79. Fosun-Pharmaceutical Business Overview Table 80. Fosun-Pharmaceutical mRNA COVID-19 Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Fosun-Pharmaceutical mRNA COVID-19 Vaccine Product Portfolio Table 82. Fosun-Pharmaceutical Recent Development Table 83. Moderna Company Information Table 84. Moderna Business Overview Table 85. Moderna mRNA COVID-19 Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Moderna mRNA COVID-19 Vaccine Product Portfolio Table 87. Moderna Recent Development Table 88. Key Raw Materials Table 89. Raw Materials Key Suppliers Table 90. mRNA COVID-19 Vaccine Distributors List Table 91. mRNA COVID-19 Vaccine Customers List Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. mRNA COVID-19 Vaccine Product Image Figure 2. Global mRNA COVID-19 Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA COVID-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global mRNA COVID-19 Vaccine Sales (2021-2032) & (k units) Figure 5. Global mRNA COVID-19 Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global mRNA COVID-19 Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Non-replicating mRNA Vaccine Image Figure 10. Self-amplifying mRNA Vaccine Image Figure 11. Global mRNA COVID-19 Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global mRNA COVID-19 Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global mRNA COVID-19 Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global mRNA COVID-19 Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global mRNA COVID-19 Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global mRNA COVID-19 Vaccine Sales Value Share by Type (2021-2032) Figure 17. Children Image Figure 18. Adults Image Figure 19. Global mRNA COVID-19 Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global mRNA COVID-19 Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global mRNA COVID-19 Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global mRNA COVID-19 Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global mRNA COVID-19 Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global mRNA COVID-19 Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global mRNA COVID-19 Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global mRNA COVID-19 Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global mRNA COVID-19 Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global mRNA COVID-19 Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America mRNA COVID-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America mRNA COVID-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe mRNA COVID-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe mRNA COVID-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific mRNA COVID-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific mRNA COVID-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America mRNA COVID-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America mRNA COVID-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa mRNA COVID-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa mRNA COVID-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. mRNA COVID-19 Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. mRNA COVID-19 Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Non-replicating mRNA Vaccine
  • Self-amplifying mRNA Vaccine
Applications
  • Children
  • Adults
Companies covered
  • CSPC Pharmaceutical
  • CanSino Biologicals
  • Pfizer
  • Fosun-Pharmaceutical
  • Moderna

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global mRNA COVID-19 Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global mRNA COVID-19 Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global mRNA COVID-19 Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 mRNA COVID-19 Vaccine Market Dynamics
  1. 2.1 mRNA COVID-19 Vaccine Industry Trends
  2. 2.2 mRNA COVID-19 Vaccine Industry Drivers
  3. 2.3 mRNA COVID-19 Vaccine Industry Opportunities and Challenges
  4. 2.4 mRNA COVID-19 Vaccine Industry Restraints
3 mRNA COVID-19 Vaccine Market by Company
  1. 3.1 Global mRNA COVID-19 Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global mRNA COVID-19 Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global mRNA COVID-19 Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global mRNA COVID-19 Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global mRNA COVID-19 Vaccine Company Ranking (2024-2026)
  6. 3.6 Global mRNA COVID-19 Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global mRNA COVID-19 Vaccine Company Product Type and Application
  8. 3.8 Global mRNA COVID-19 Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global mRNA COVID-19 Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 mRNA COVID-19 Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 mRNA COVID-19 Vaccine Market by Type
  1. 4.1 mRNA COVID-19 Vaccine Type Introduction
  2. 4.1.1 Non-replicating mRNA Vaccine
  3. 4.1.2 Self-amplifying mRNA Vaccine
  4. 4.2 Global mRNA COVID-19 Vaccine Sales Volume by Type
  5. 4.2.1 Global mRNA COVID-19 Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global mRNA COVID-19 Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global mRNA COVID-19 Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global mRNA COVID-19 Vaccine Sales Value by Type
  9. 4.3.1 Global mRNA COVID-19 Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global mRNA COVID-19 Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global mRNA COVID-19 Vaccine Sales Value Share by Type (2021-2032)
5 mRNA COVID-19 Vaccine Market by Application
  1. 5.1 mRNA COVID-19 Vaccine Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adults
  4. 5.2 Global mRNA COVID-19 Vaccine Sales Volume by Application
  5. 5.2.1 Global mRNA COVID-19 Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global mRNA COVID-19 Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global mRNA COVID-19 Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global mRNA COVID-19 Vaccine Sales Value by Application
  9. 5.3.1 Global mRNA COVID-19 Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global mRNA COVID-19 Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global mRNA COVID-19 Vaccine Sales Value Share by Application (2021-2032)
6 mRNA COVID-19 Vaccine Regional Sales and Value Analysis
  1. 6.1 Global mRNA COVID-19 Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global mRNA COVID-19 Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global mRNA COVID-19 Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global mRNA COVID-19 Vaccine Sales by Region (2027-2032)
  5. 6.3 Global mRNA COVID-19 Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global mRNA COVID-19 Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global mRNA COVID-19 Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global mRNA COVID-19 Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global mRNA COVID-19 Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America mRNA COVID-19 Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America mRNA COVID-19 Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe mRNA COVID-19 Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe mRNA COVID-19 Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific mRNA COVID-19 Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific mRNA COVID-19 Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America mRNA COVID-19 Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America mRNA COVID-19 Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa mRNA COVID-19 Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa mRNA COVID-19 Vaccine Sales Value Share by Country, 2025 VS 2032
7 mRNA COVID-19 Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global mRNA COVID-19 Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global mRNA COVID-19 Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global mRNA COVID-19 Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global mRNA COVID-19 Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global mRNA COVID-19 Vaccine Sales by Country (2027-2032)
  6. 7.4 Global mRNA COVID-19 Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global mRNA COVID-19 Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global mRNA COVID-19 Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt mRNA COVID-19 Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt mRNA COVID-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt mRNA COVID-19 Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSPC Pharmaceutical
  2. 8.1.1 CSPC Pharmaceutical Company Information
  3. 8.1.2 CSPC Pharmaceutical Business Overview
  4. 8.1.3 CSPC Pharmaceutical mRNA COVID-19 Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSPC Pharmaceutical mRNA COVID-19 Vaccine Product Portfolio
  6. 8.1.5 CSPC Pharmaceutical Recent Developments
  7. 8.2 CanSino Biologicals
  8. 8.2.1 CanSino Biologicals Company Information
  9. 8.2.2 CanSino Biologicals Business Overview
  10. 8.2.3 CanSino Biologicals mRNA COVID-19 Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CanSino Biologicals mRNA COVID-19 Vaccine Product Portfolio
  12. 8.2.5 CanSino Biologicals Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer mRNA COVID-19 Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer mRNA COVID-19 Vaccine Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Fosun-Pharmaceutical
  20. 8.4.1 Fosun-Pharmaceutical Company Information
  21. 8.4.2 Fosun-Pharmaceutical Business Overview
  22. 8.4.3 Fosun-Pharmaceutical mRNA COVID-19 Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Fosun-Pharmaceutical mRNA COVID-19 Vaccine Product Portfolio
  24. 8.4.5 Fosun-Pharmaceutical Recent Developments
  25. 8.5 Moderna
  26. 8.5.1 Moderna Company Information
  27. 8.5.2 Moderna Business Overview
  28. 8.5.3 Moderna mRNA COVID-19 Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Moderna mRNA COVID-19 Vaccine Product Portfolio
  30. 8.5.5 Moderna Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 mRNA COVID-19 Vaccine Value Chain Analysis
  2. 9.1.1 mRNA COVID-19 Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 mRNA COVID-19 Vaccine Sales Mode & Process
  6. 9.2 mRNA COVID-19 Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 mRNA COVID-19 Vaccine Distributors
  9. 9.2.3 mRNA COVID-19 Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst